Document is current

Article History

Received: 12 December 2025

Accepted: 11 May 2026

First Online: 29 May 2026

Declarations

:

: This prospective registry study was approved by the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg, Germany (approval number: 2024 − 404 M-§ 47 (3) MPDG). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent to participate was obtained from all patients prior to inclusion.

: Not applicable.

: C.D. reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses. D.B. reports NB Capital ApS (Consultation, personal fees), PharmaMar GmbH (speaker) and AstraZeneca GmbH (speaker). J.B-H. reports AstraZeneca speaker fees and consulting honoraria EbaMed SA. F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from OncoMANGETx, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG and patent EP4119191A1. M.F.F reports travel expenses from Siemens Healthineers AG. M.Eh reports Siemens Healthineers AG speaker fees and travel expenses.